Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Waltz

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
American Journal of Respiratory and Critical Care Medicine|December 14, 2002
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosisRonald L Gibson, Julia Emerson, Sharon McNamara, et al.
American Journal of Respiratory and Critical Care Medicine|June 2, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension StudyClaire Wainwright, Susanna A McColley, Paul McNally, et al.
The Lancet. Respiratory Medicine|December 23, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trialSivagurunathan Sutharsan, Edward F McKone, Damian G Downey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 4, 2025
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatmentEdith T Zemanick, Bonnie Ramsey, Dorota Sands, et al.
The New England Journal of Medicine|May 19, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World StudyCarlo Castellani, Pedro Mondejar-Lopez, Fredrick Van Goor, et al.
The New England Journal of Medicine|October 19, 2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesDominic Keating, Gautham Marigowda, Lucy Burr, et al.
The New England Journal of Medicine|November 8, 2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del AllelePeter G Middleton, Marcus A Mall, Pavel Dřevínek, et al.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
American Journal of Respiratory and Critical Care Medicine|April 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Extension StudyCori L Daines, Deepika Polineni, Elizabeth Tullis, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
American Journal of Respiratory and Critical Care Medicine|December 14, 2002
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosisRonald L Gibson, Julia Emerson, Sharon McNamara, et al.
American Journal of Respiratory and Critical Care Medicine|June 2, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension StudyClaire Wainwright, Susanna A McColley, Paul McNally, et al.
The Lancet. Respiratory Medicine|December 23, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trialSivagurunathan Sutharsan, Edward F McKone, Damian G Downey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 4, 2025
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatmentEdith T Zemanick, Bonnie Ramsey, Dorota Sands, et al.
The New England Journal of Medicine|May 19, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World StudyCarlo Castellani, Pedro Mondejar-Lopez, Fredrick Van Goor, et al.
The New England Journal of Medicine|October 19, 2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesDominic Keating, Gautham Marigowda, Lucy Burr, et al.
The New England Journal of Medicine|November 8, 2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del AllelePeter G Middleton, Marcus A Mall, Pavel Dřevínek, et al.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
American Journal of Respiratory and Critical Care Medicine|April 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Extension StudyCori L Daines, Deepika Polineni, Elizabeth Tullis, et al.
Pageof 4